Tag: hepatic
Delcath Systems announces US FDA acceptance of Hepzato Kit new drug...
Delcath Systems has announced in a company press release that the US Food and Drug Administration (FDA) has accepted its (Delcath's) new drug application...
Delcath Systems announces updated results from CHOPIN phase 1b trial
Delcath Systems has shared in a press release the publication of updated results from the phase 1b CHOPIN Trial, conducted at Leiden University Medical...
How liver venous deprivation is “pushing limits”
Both the Andreas Gruentzig Lecture at this year’s Cardiovascular and Interventional Radiological Society of Europe meeting (CIRSE; 10–14 September, Barcelona, Spain) and a presentation...
HKUMed discovers new trimodality therapy for locally advanced liver cancer
A phase II clinical study on a trimodality therapy (START-FIT), conducted by the Departments of Surgery and Clinical Oncology, School of Clinical Medicine, University...
Interventional News’ top 10 most popular stories of December 2022
Interventional News’ most popular stories as 2022 came to a close included news of a US Food and Drug Administration clearance for a new...
Results of single-centre study of Chemosat hepatic delivery system published in...
Delcath Systems announced the publication of a retrospective analysis of patients who underwent a percutaneous hepatic perfusion procedure (PHP) with Chemosat for the treatment...
Results of a multicentre study of Chemosat hepatic delivery system published...
Delcath Systems has announced the publication of a retrospective analysis of patients who underwent a percutaneous hepatic perfusion procedure (PHP) with Chemosat at three...
Peritransplant vascular complications: An IR approach
In the USA, liver transplantation continues to be the best chance at long-term survival for patients suffering from the sequelae of end-stage liver disease....
Percutaneous melphalan perfusion can induce significant responses in uveal liver metastases
Percutaneous hepatic perfusion with melphalan for the treatment of metastatic uveal melanoma (mUM) offers a hepatic response rate of 66.7% and good progression-free survival...
